Skin Elements Limited has completed a $2.5 million placement to fund the commercial rollout of its ECO Nurture bio-stimulant, targeting sustainable kiwifruit orchard protection in New Zealand.
- Completed $2.5 million placement with shares and options issued
- Funds to support commercialisation of ECO Nurture plant bio-stimulant
- Focus on sustainable protection for New Zealand kiwifruit orchards
- Strong trial results underpin confidence in product efficacy
- Placement led by 62 Capital Pty Ltd with shareholder approval secured
Placement Completion and Capital Raise
Skin Elements Limited (ASX – SKN) has successfully completed a $2.5 million capital raise through a two-tranche placement, issuing over 1 billion shares and more than 600 million options to sophisticated and professional investors. The latest tranche, worth $2.185 million, was allotted at a modest price of $0.002 per share, accompanied by options exercisable at $0.006 each, expiring in December 2028. This funding round follows shareholder approval at the company’s recent Annual General Meeting, underscoring investor confidence in Skin Elements’ strategic direction.
Driving Commercialisation of ECO Nurture
The proceeds from the placement are earmarked to accelerate the commercialisation of Skin Elements’ flagship biotechnology product, ECO Nurture. This natural plant bio-stimulant is designed as a sustainable alternative to chemical sprays, initially targeting the kiwifruit orchards of New Zealand, a significant agricultural market known for its stringent quality standards and environmental awareness. ECO Nurture’s plant-based formulation aligns with growing global demand for eco-friendly crop protection solutions.
Market Opportunity and Product Potential
Skin Elements’ executive chairman, Peter Malone, highlighted the strong support from both new and existing investors, emphasizing the company’s readiness to launch its commercial strategy. The company’s testing and trial programs have reportedly delivered promising results, providing confidence in ECO Nurture’s efficacy against crop diseases. This positions the product well to capture market share as growers seek sustainable, effective alternatives to traditional chemical treatments.
Strategic Implications and Future Outlook
With the capital raise complete, Skin Elements is poised to transition from development to commercial deployment, a critical phase that will test market acceptance and operational execution. The involvement of 62 Capital Pty Ltd as sole lead manager reflects a professional approach to funding and investor relations. Looking ahead, the company’s ability to scale production, secure regulatory approvals, and build distribution channels will be key determinants of success.
Skin Elements also benefits from a diversified portfolio of natural biotechnology products, including hospital-grade disinfectants and organic skincare lines, which may provide cross-promotional opportunities and revenue stability as ECO Nurture gains traction.
Bottom Line?
Skin Elements’ fresh capital injection sets the stage for ECO Nurture’s commercial debut, but market adoption and execution will be the true tests ahead.
Questions in the middle?
- How quickly can Skin Elements scale ECO Nurture production to meet commercial demand?
- What regulatory hurdles remain for ECO Nurture’s widespread use in New Zealand and beyond?
- How will existing shareholders respond to dilution from the large share and option issuance?